Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akari TherapeuticsAKTX 32 5-Year Yield-on-Cost % is 0.00 as of Aug. 14, 2026. GuruFocus rates AKTX with a GF Score™ of 32/100. Among 150 Biotechnology companies, Akari Therapeutics ranks worse than 666666% on this metric.
Akari Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Akari Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
AKTX's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Akari Therapeutics 5-Year Yield-on-Cost % Related Terms
AKTX vs MBRX, INTI, TPST: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Akari Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Akari Therapeutics (AKTX) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Akari Therapeutics and its competitors. According to the industry distribution chart, Akari Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry.
Is Akari Therapeutics' 5-Year Yield-on-Cost % too high?
Akari Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Akari Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' 5-Year Yield-on-Cost % compare to MBRX and INTI?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Akari Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.60, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Akari Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akari Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score
Get the complete analysis for AKTX
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTX has been successfully added to your 
